Faculty Collaboration Database

Hepatitis C and Treatment in Patients with Chronic Kidney Disease. Dis Mon 2021 Feb;67(2):101017

Date

06/20/2020

Pubmed ID

32553421

DOI

10.1016/j.disamonth.2020.101017

Scopus ID

2-s2.0-85086432186 (requires institutional sign-in at Scopus site)   3 Citations

Abstract

Hepatitis C virus (HCV) is associated with increased mortality and morbidity in patients with chronic kidney disease (CKD). The early detection and treatment of Hepatitis C associated with kidney disease is paramount to preventing the progressive loss of kidney function. HCV treatment until the advent of direct acting anti-viral agents (DAAs) was limited to interferon and ribavirin. Interferon and ribavirin treatment resulted in only modest success but with frequent adverse events and poor tolerability. Furthermore, interferon and ribavirin could not be used in certain patient populations including those with advanced CKD, were on dialysis, or those who have received a kidney transplant. DAAs have now made treatment possible in these sub-groups with a sustained viral response (SVR) of 90-100% and minimal side effects. DAAs have helped increase transplant rates by allowing for the use of HCV positive kidneys in recipients who are HCV negative. Although the choice of DAAs should be carefully considered and based on patient characteristics, concomitant medications, and HCV genotype.

Author List

Jalota A, Lindner BK, Thomas B, Lerma EV

Author

Beje Thomas MD Associate Professor in the Medicine department at Medical College of Wisconsin

MESH terms used to index this publication - Major topics in bold

Antiviral Agents
Hepacivirus
Hepatitis C
Hepatitis C, Chronic
Humans
Kidney Failure, Chronic
Kidney Transplantation
Patient Selection
Renal Dialysis
Renal Insufficiency, Chronic
Ribavirin